At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 204 enrolled
Drug / intervention
Prasugreldrug
Likely dose
Prasugrel 3.75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IV, Non-comparative, Open Label, Multicenter, 28-Week Switching Study of Prasugrel Maintenance Dose From Clopidogrel in Patients With Acute Coronary Syndrome (ACS) Who Underwent a Percutaneous Coronary Intervention (PCI) in Taiwan
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company·interventional·Posted Sep 14, 2018·Updated Nov 12, 2021
In Brief
A Phase 4 clinical trial evaluating Prasugrel for Acute Coronary Syndrome (ACS). Completed, enrolled 204 participants across 10 sites.
Detailed Summary
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome (ACS)
CountriesTaiwan
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartOct 2018
Primary CompletionAug 2020
TodayJul 2026
First PostedSep 14, 2018
Enrollment StartOct 16, 2018
Primary CompletionAug 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.8 years ago
Interventions
Prasugreldrug
Prasugrel, oral tablets, containing 3.75 mg per tablet